In a 3-week period, samples of peritoneal fluid, lymph nodal biopsy, blood, gastric aspirate and urine were investigated for the presence of mycobacteria. Although they were smear-negative for acid-fast bacilli (with the exception of the gastric juice, which was weakly positive) all, but the urine sample, yielded positive mycobacterial cultures after an incubation ranging from 2 to 4 weeks.
All the isolates (which were photochromogenic) were identified using the commercial DNA probe INNO LiPA (Innogenetics, Ghent, Belgium) as M. simiae, an identification that was in agreement with the HPLC pattern of cell wall mycolic acids.
Antimycobacterial treatment with ethambutol (20 mg/kg a day), clarithromycin (15 mg/kg twice a day) and ciprofloxacin (30 mg/kg a day) was undertaken.
Susceptibility testing performed by the broth microdilution method, as recommended by the Clinical and Laboratory Standards Institute (previously NCCLS) [5] for nontuberculous mycobacteria, revealed high minimum inhibitory concentration values with ciprofloxacin, clarithromycin, ethambutol, linezolid, rifampin, streptomycin, and moxifloxacin, with susceptibility only to rifabutin and amikacin (Table 1) . Accordingly, amikacin (30 mg/kg a day) was added to the treatment regimen and the patient became afebrile within a few days. Abdominal cramps resolved within one month of treatment but amikacin monotherapy was continued for 6 weeks, because of relapsing fever with interruption of treatment. Currently the child, who is back in Eritrea, is well and his CD4 cell count is 400 cells/µl.
One year later, during a polycentric study of M. simiae (in preparation), all of the strains of our laboratory collection identified as belonging to M. simiae species were submitted to genetic sequencing of the 16S rRNA gene. Further investigation of the strain reported here revealed 100% identity with the species M. sherrisii, and the genetic sequencing of a 440 base pair segment of the gene encoding for the 65KD heat shock protein confirmed this identification.
Our report corroborates the lack of information available concerning M. sherrisii. This species may be commonly misidentified as M. simiae using HPLC or commercial DNA probes [4] as well as with conventional and biochemical tests [2] . Like M. simiae, M. sherrisii is highly drug resistant in vitro and, as with many non-tuberculous mycobacteria, may cause disease in HIV-positive patients.
Of the two previously reported cases, the patient with AIDS was successfully treated with a combination regimen of clarithromycin, rifabutin and moxifloxacin [3] , whereas the other patient did not benefit from a standard ________________________________________________________________________________Correspondence 1497
antituberculosis treatment [4] . The source and the number of isolations unquestionably support the clinical significance of the case reported here. The availability of the in-vitro antimicrobial susceptibility, which allowed us to adjust the treatment, played a major role in the excellent response of the patient. Moreover the efficacy of treatment allowed us to contain a disseminated mycobacterial infection while stable immune reconstitution was developing, with the initial worsening of the clinical picture being probably imputable to a precocious immune reconstitution syndrome, often associated with nontuberculous mycobacteria [6] .
